Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Lilly buys in another PI3Kα inhibitor
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
